Tag Archives: innovation

Call for Innovation Challenge Applicants

17 Jul

Life Science Nation invites all eligible early stage life science companies to apply to Innovation Challenge to showcase their technologies.

Companies from all categories of life science are encouraged to apply to Innovation Challenge for RESI Healthtech Week. Eligible companies can apply to Day 1, the First Coast Innovator’s Gathering, Day 2 RESI Global Partnering or both. Applicants will have the opportunity for excellent visibility among investors and strategic partners.

LSN is now accepting applications! The deadline is July 27, 2018.

For the first time this fall, Life Science Nation will have two days of Innovation Challenge competition as part of the RESI Healthtech Week (September 5-7, 2018). The Innovation Challenge offers selected companies the chance to gain more visibility from the early-stage investors in attendance.

Day 2 Redefining Early Stage Investments

All early-stage life science companies are eligible to apply. Finalists will be highlighted in multiple outlets:

  • Your country and technology highlighted at the conference
  • All conference attendees will have the chance to “invest” RESI Cash in their favorite technologies
  • LSN Newsletter Announcement to a readership of 20,000+
  • Featured on RESI Conference website Featured in the printed and online program guide
  • Winners will be announced during the cocktail reception
  • It is FREE to apply, click here.

Day 1, First Coast Innovation Challenge

All early-stage life science companies from DC through Boston are eligible to apply. Applicants will be highlighted in multiple outlets:

  • 10 finalists will be selected to pitch to a panel of investors
  • Applicants present a poster of their technology
  • All featured in the printed and online program guide
  • Attendees have access to partnering platform
  • Attendees have access to early-stage investor panels
  • Attendance on Day 1 for companies is $300, click here.

9 Hamilton Place, Suite 2B, Boston, MA 02108 +1 617-600-0668 | resi@lifesciencenation.com

New CFDA Regulations Already Showing Benefits for China’s Biotech Innovation

1 Mar

By James Huang, Research Analyst, LSN

james-wpWithin the last few months, China has been formally rolling out their new CFDA regulations that have given startups and new technology developers in China all sorts of benefits. These benefits include allowing the submission of data from clinical trial sites outside of China, allowing more Chinese hospitals to run trials, and allowing drug makers who are waiting for the green light on a safety study to go ahead if they haven’t heard back from the CFDA within 60 days.

All these regulation changes have seen a big boom to China’s biotech innovations. In fact, many Taiwanese companies have seen this regulatory shift as an opportunity to get into the Chinese market. Companies such as Taiwan Liposome (TLC) have started joint ventures with Chinese investors in order to run trials and commercialize their products in China. With the ability to submit their clinical trial data from Taiwan and start their new trials more quickly in China, many of these companies expect to see NDA filings for their assets by the end of the year.

Another highlight of this new regulatory system is that CRISPR human trials have already started within Chinese hospitals. CRISPR in the US, on the other hand, has yet to receive any approval or the go ahead for such trials. Some describe this discrepancy as being the result of China’s lack of regulations. However, that is not necessarily the case. China’s new regulations are geared towards pushing new innovative technologies into trials and out onto market as quickly as possible and has the benefit of being a newly reformed system. In contrast, the US FDA is a much older system using regulations that have been built upon for years, resulting in a much slower and more meticulous process.

Therefore, it might be an advantageous for startups to consider working with Chinese investors through joint ventures. The benefits of having an accelerated clinical trial process with reduced trial costs may be worth the pain of forming a joint venture with a qualified Chinese partner. Of course, while the process of finding a qualified Chinese partner and working with them may be tedious on its own, it definitely should not be immediately discounted. Given how the times are changing, a global outlook towards potential partners and opportunities is becoming more and more necessary in order to succeed.

Digital Health: Two Panels Showcase the New Innovation Frontier at RESI X

25 Aug

By Lucy Parkinson, Director of Research, LSN

Boston is known for being the hub of the biotech world. But as software is eating the world, innovators are finding new avenues for digitization of healthcare. Some are tackling inefficiencies and bottlenecks in the healthcare delivery system; others are using big data algorithms to explore biological processes, make new discoveries, or find new signals in population health data.

RESI Boston will feature two panels that explore this collision between software and health. The Healthcare IT session will look at the current landscape in digital health investment. What kind of solutions are investors excited about, and how do they assess startups in this increasingly crowded sector?

Moderated by Michael A. Greeley, General Partner, Flare Capital Partners, the panelists are:

In Big Data in Healthcare, RESI will take a laser focused look at the new possibilities that data science is creating in biotech and health innovation. Five investors will explore what they’re looking for in a big data opportunity. The participants will be:

If you’d like to catch these panels in person, you can register for RESI now.


RESI Boston Panel Announcement: Medtech Strategic Firms Partnering for Innovation

4 Aug

By Lucy Parkinson, Director of Research, LSN

It’s well known that big pharma firms are often looking to partner early.  Many major medical device companies are also looking outward for innovation, and at RESI Boston, five experienced corporate investors will explain how they use early stage device investments to strategic effect.  This panel will cover how medical device entrepreneurs should approach a larger company for an investment or development partnership, and what kinds of investment these major players are currently focused on.

These five panelists will be sharing their expertise with RESI’s audience:

If you’re interested in hearing from these firms on their varied approaches to early stage innovation, you can register for RESI now.


MaRS Collaborates with Life Science Nation and Johnson & Johnson Innovation to Host RESI in Toronto

12 Apr

TORONTO – April 12, 2016 – MaRS Discovery District (MaRS) is collaborating with Life Science Nation (LSN) and Johnson & Johnson Innovation, JLABS (JLABS) to bring the Redefining Early Stage Investments (RESI) Conference to Toronto on June 23, 2016.

The RESI Conference series brings together fundraising CEOs and early stage investors from around the globe, providing the opportunity for dialogue and relationship building, with the goal of eventual capital allocations.

“MaRS supports over 250 Canadian-grown early stage health technology startups,” said Dianne Carmichael, managing director, health innovation & venture services at MaRS. “Our goal is to provide these young emerging ventures with the best connections to investors and industry to help them scale internationally. The Redefining Early Stage Investment (RESI) conference series has a strong track record of attracting global early stage investors. We’re delighted to bring them to MaRS this summer to build on the success of our HealthKick conferences.”

RESI on MaRS will connect cutting-edge health technologies with a broad audience of investors and industry leaders, including: angel syndicates, private wealth firms, corporate venture capitalists, venture philanthropy groups, foundations and endowments, big pharma and virtual pharma companies, mid-level private equity firms, government organizations, and venture capital investors. The conference will also include 16 panel sessions with pharmaceutical, medical device, biotech, consumer health and healthcare IT investors.

The annual MaRS HealthKick Innovation Challenge will happen this year as part of RESI on MaRS. The Dragons’ Den-like Challenge sets 30 selected companies up to demonstrate their technology and business while competing for prizes in a full-day exhibition to investors and potential partners.

“The MaRS Centre in Toronto represents the 4th venue for our North American RESI Conference series. Now fundraising CEOs and scientist entrepreneurs can meet investors every 90 days — Boston took place in September (RESI Boston), San Francisco in January (RESI @ JPM), Houston is in April (RESI @ TMCx) and now Toronto in June (RESI on MaRS),” said Dennis Ford, CEO at LSN and creator of the RESI Conference Series.

Speakers and participating health ventures will be announced in April.

About MaRS Discovery District

MaRS Discovery District in Toronto is one of the world’s largest urban innovation hubs, supporting a new generation of makers and innovators who aim to make the world a better place by creating solutions that address key societal challenges. It is a community that encourages entrepreneurial thinking through education programs and events, and helps startups launch, grow and scale. MaRS supports over 1,000 ventures.

About Life Science Nation

Life Science Nation (LSN) accelerates the funding of early stage life science firms through its Match.com-like sourcing platform for private investment and enables CEOs to be more efficient in their capital-raising efforts. LSN owns and operates the Redefining Early Stage Investments (RESI) conference series.

For more information, please contact the RESI Team at resi@lifesciencenation.com or 617-600-0668

RESI Panel Announcement: Explore Houston’s Innovation Drive in The Future Is Now

7 Apr

By Lucy Parkinson, Director of Research, LSN

Houston is on a roll in life science technology. In 2015, the TMCx Accelerator ran its debut class of new healthcare companies; 2016 has already seen the arrival of JLABS@TMC, and AT&T Foundry will open in Houston soon. These facilities will collectively support dozens of new healthcare inventions, fostering a diverse ecosystem of early stage life science companies in Houston. This RESI panel, The Future Is Now, will cover these new developments and explain why Houston’s moment for has come.

Moderated by Nicole Fisher, Founder & CEO, HHR Strategies, the panel will feature:

This unique session will explore how Houston has become a health innovation hub that attracts major strategic firms to open facilities for entrepreneurs. The participants will also describe the innovation that’s happening at their new facilities in Houston, how they’re supporting new technologies that are coming out of Texas Medical Center’s instutitions, and what kinds of innovators they’re looking to work with.

If you’d like to be there in person, it’s not too late to sign up to join RESI@TMCx.


Innovations at RESI: Diagnostics Gone Wild

10 Oct

By Lucy Parkinson, Research Analyst, LSN

When a potential investor approaches a diagnostics company, some of the first words out of their mouth are likely to be “How are you going to deal with the reimbursement problem?” At the Redefining Early Stage Investments Conference, we heard from diagnostic entrepreneurs who were rethinking the reimbursement model from the ground up.

A traditional business model for a diagnostics company involves persuading care providers that they ought to use the test, and then convincing HMOs that they ought to reimburse it. For a new product, this can be a tough sell; insurance plans often won’t specifically cover an innovative test, leaving the company to scratch for reimbursement on a case-by-case basis. They have to prove over and over that the test is more accurate or more cost-effective than the competition. Even companies providing an established product may find their revenues at the mercy of Centers for Medicare & Medicaid Services billing coding changes. Given these challenges, how can a diagnostics company build an attractive business plan that will win over investors?

Find the gaps in a divided marketplace. Most healthcare practitioners work in a highly specific area, yet many medical conditions manifest in ways that cut across these divisions. Sometimes, linked comorbidities are split between two different areas of medicine – for example, diabetes and eye problems. A diabetic patient might not have the time or inclination (or even the insurance coverage) to get their eyes checked out. An innovative business plan for an ophthalmic diagnostic might therefore include targeting clinics that deal with diabetes, and vice versa. We’ve heard from diabetes diagnostics looking to eye clinics for a new market; these related yet divided conditions show up all over the life science map, and diagnostics for many indications could take advantage of them.

Bypass the gatekeepers. We heard one diagnostics CEO say “I want to see people using our device in Walmart and CVS.”  If you have the right product – in this case, a device for a huge potential market that can deliver an automated result in minutes at a sub-$100 cost – you can seek direct routes to consumers. Similarly, the consumer market for wearable medical devices is exploding; this is, thus far, the only subsector of the medical device space where a company has successfully crowdsourced development of a product.

Rethink what your technology can do.  We heard from the developer of a diagnostic test so sensitive and robust that it can be administered entirely by mail, with the patient receiving a diagnostic kit at home and returning a swab straight to the diagnostic lab.  What is this company’s new business idea for this powerful new platform? Crowdsourced clinical trials. Rather than trial participants having to be regularly monitored by researchers at one location, they can be enrolled in the trial and then participate remotely, anywhere, anytime, bringing a huge increase in scale and a decrease in costs (including for participants).

Diagnostics might seem like a crowded field, but if your technology is powerful, a little innovative thinking about what it can do can completely change your approach to attaining revenue. You’ll stand out to investors if the reimbursement problem isn’t a problem to you at all.

%d bloggers like this: